Compare CBC & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | BLCO |
|---|---|---|
| Founded | 1902 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Ophthalmic Goods |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.1B |
| IPO Year | 2025 | 2022 |
| Metric | CBC | BLCO |
|---|---|---|
| Price | $36.85 | $19.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $36.30 | $21.93 |
| AVG Volume (30 Days) | 867.8K | ★ 980.7K |
| Earning Date | 10-27-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ 25.90 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $8.23 | $7.83 |
| Revenue Next Year | $5.79 | $5.90 |
| P/E Ratio | $26.20 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $22.50 | $14.65 |
| 52 Week High | $38.79 | $21.40 |
| Indicator | CBC | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 47.83 |
| Support Level | $30.44 | $15.30 |
| Resistance Level | $38.77 | $21.38 |
| Average True Range (ATR) | 0.83 | 0.59 |
| MACD | -0.23 | -0.16 |
| Stochastic Oscillator | 10.28 | 2.76 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.